A phase 2 trial to assess efficacy and safety of Enhertu in HER2-mutant advanced lung cancer patients with asymptomatic brain metastases
- Conditions
- Neoplasms
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 27
1. Age 20 or more than 20 years-old
2. Histologically confirmed, locally advanced and unresectable NSCLC not amenable to treatment with curative intent (surgery or chemoradiotherapy) or recurrent or de novo-metastatic non-squamous NSCLC (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology) locally advanced or metastatic non-squamous NSCLC (Participants with mixed histology are eligible if adenocarcinoma is the predominant histology).
3. Activating HER2-mutation documented by NGS in tissue or plasma (include activating HER2 mutation in exon 19 or 20, i.e. , Exon 20: A775_G776insYVMA insertion/duplication; point mutations, L755S and G776C; transmembrane and the juxtamembrane domains G660D, R678Q, E693K and Q709Ldocumented mutation) regardless of HER2 expression.
HER2 expression on tissue based on IHC (IHC 1+, 2+, or 3+)
4. Asymptomatic brain metastases at baseline without local therapy for brain metastasis or stable brain metastasis after local therapy (WBRTx, SRS, GKS etc), which is defined as patients who are not requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
5. Prior failure on any systemic chemotherapy platinum-based chemotherapy
6. Measurable disease according to RECIST version 1.1Response Assessment in Neuro-Oncology Criteria (RANO)
7. LVEF = 50% within 28 days before randomization/enrollmentfirst dose .
8. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1.
9. Adequate organ and bone marrow function within 14 days before randomization/enrolmentfirst dose as described in Table 1 below. All parameters must meet the inclusion criteria on the same day, and must be the most recent results available.
Table 1 Parameters for Adequate Organ and Bone Marrow Function
Adequate bone marrow function
Platelet Count = 100000/mm3.
Haemoglobin = 9.0 g/dL
Absolute neutrophil count = 1500/mm3
Adequate hepatic function
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3×ULN (< 5×ULN in participants with liver metastases)
Total Bilirubin = 1.5×ULN if no liver metastases or < 3×ULN in the presence of documented Gilbert’s syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline
Serum albumin = 2.5 g/dL
Adequate renal function
CrCL = 30 mL/min as determined by Cockcroft Gault (using actual body weight).
Males:
CLcr (mL/min) = [140 — age (years)] × weight (kg) /72 × serum creatinine (mg/dL)
Females:
(CLcr (mL/min) = [140 — age (years)] × weight (kg) /72 × serum creatinine (mg/dL) × 0.85
Adequate blood clotting function
International normalised ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time = 1.5 × ULN
*CrCL = calculated creatinine clearance; ULN = upper limit of normal
10. Adequate treatment washout period before enrollment, defined in Table 2 below:
Table 2 Adequate treatment washout periods
Treatment / Minimum Washout Period
Major Surgery = 4 weeks
Radiation Therapy including palliative stereotactic radiation therapy to chest = 4 weeks
Palliative stereotactic radiation therapy to other anatomic areas including whole brain radiation, bone radiation and GKS = 2 weeks
Anti-Cancer chemotherapy [Immunotherapy (non-antibody based therapy)] = 43 weeks
Antibody based anti-cancer therapy = 4 weeks
Targeted agents and small molecules = 242 weeks or 5 half-lives, whichever is longer
TKIs approved for treat
1. Active brain metastases that require intervention
2. Leptomeningeal metastases
3. Systemic antitumor therapy within 28 days(Targeted therapy, = 2 weeks or 5 half-lives) before initiation of T-DXd
4. Radiation therapy(excluding palliative stereotactic radiation therapy to chest) or gamma-knife surgery within 2weeks before initiation of T-DXd
5. Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject’s participation in the clinical study or evaluation of the clinical study results.
6. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with untreated but clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment/randomization.
7. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade = 2 or baseline
8. Patients with a medical history of myocardial infarction (MI) within 6 months before enrolment, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV),
9. History of (non-infectious) ILD / pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
10. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.(Using for prophylactic antibiotics is allowed.)
11. Active primary immunodeficiency, known uncontrolled active HIV infection or active hepatitis B or C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1 Day 1. Subjects with past or resolved hepatitis B virus (HBV) infection who are anti-HBc positive (+) are eligible only if they are HBsAg negative (-).
12. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Subjects should be tested for HIV prior to randomization/enrollment if required by local regulations or institutional review board (IRB)/ethics committee (EC).
13. Receipt of live, attenuated vaccine within 30 days prior to the first dose of trastuzumab deruxtecan. Receipt of live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first dose of trastuzumab deruxtecan. Note: Participants, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of study intervention.
14. Clinically significant pleural effusion, ascites or pericardial effusion that requires drainage.(Stable
15. Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g. pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.)
16. Any autoimmune, connective tissue or inflammatory disorders (e.g. Rheumat
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Median Intracranial Progression-free survival(icPFS) as defined by RANO criteria
- Secondary Outcome Measures
Name Time Method Progression free survival as defined by RECIST 1.1;Median Intracranial Progression-free survival as defined by RECIST 1.1;Intracranial objective response rate by RECIST 1.1;Overall response rate as defined by RECIST 1.1;Duration of response as defined by RECIST 1.1;Disease control rate as defined by RECIST 1.1;The time from the date of initial IP administration to death due to any cause;Site of next progression ;AEs/SAEs, Vital signs, Collection of clinical chemistry/haematology parameters, ECGs